In China, ovarian cancer is one of the tumors with the highest incidence of gynecological reproductive system, and the mortality rate ranks first among gynecological malignant tumors.
March 8, 2022 is the 112th International Women's Day.
A reporter from The Paper (www.thepaper.cn) learned from Shanghai No. 1 Maternity and Infant Health Hospital that with the publication of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)" (referred to as the new National Medical Insurance Drug Catalog) With the landing and the improvement of the clinical diagnosis and treatment level of ovarian cancer, the new treatment plan urgently needed by ovarian cancer patients has become within reach.
"This year, especially for newly diagnosed ovarian cancer patients, the first-line maintenance treatment for advanced ovarian cancer has officially entered the era of the whole population, and the policy of benefiting the people has actually brought more health protection to the masses." Professor Wang Yu, director of the health care center and chief physician of the gynecology department, said.
From January 1, 2022, the new version of the National Medical Insurance Drug List will be officially implemented nationwide, and many innovative tumor drugs and specific drugs have been included in the medical insurance list, including ovarian cancer PARP inhibitors.
"This is good news for newly diagnosed patients with advanced ovarian cancer. In the past, only patients with BRCA mutations who received maintenance therapy with PARP inhibitors could be reimbursed by medical insurance, but these patients only accounted for 15%-25%." Wang Yu Further introduction, with the implementation of the new national medical insurance drug list, all newly diagnosed advanced ovarian cancer patients, regardless of whether they have BRCA mutations, receive first-line maintenance treatment with niraparib, and are included in medical insurance reimbursement, and PARP inhibitors are used for first-line maintenance. For the first time, medical insurance reimbursement for treatment has broken through the past BRCA mutation population.
After reimbursement by medical insurance, the average monthly personal payment of local patients in Shanghai is only less than 2,000 yuan, which is more than 20,000 yuan less than before medical insurance.